Key Takeaways
- US business is the standout engine: Growth is running ahead of plan, driven by relaunches from the Endo portfolio and market share gains, pushing the company toward the higher end of its full-year EBITDA guidance.
- OneSource is fully sold out and accelerating: The injectables CDMO is backordered, with GLP demand so strong that customers are now funding capacity expansion through take-or-pay agreements, pulling forward its sell-out timeline by 6 to 8 months.
- The Biosecurity Act is a tangible tailwind: The regulatory shift has triggered a significant increase in RFPs and contract signings across drug substance, injectables, and a new softgel CDMO vertical, with management reporting a 40% win ratio.
- A new CDMO vertical is born from disruption: Global softgel capacity shortages have allowed Strides to onboard one of the world's largest consumers as its first third-party customer, with all new contracts now exclusively for outside clients.
- What to watch next quarter: The NCLT process outcome expected by calendar year-end, the Q4 commercialization of Liraglutide, and the pace of new contract signings for the European market.
US & Regulated Markets Performance
- US business: Trending ahead of the run rate, with growth fueled by relaunching products from the Endo government portfolio and capturing significant market share; one additional product achieved market leader status during the quarter.
- Product approvals: Two new products approved, one new product approved, and three products from the dormant list were launched, sustaining the commercial momentum.
- Other regulated markets: Performance was mixed; Australia and the UK delivered strong growth, while Continental Europe remained tepid as partners took longer than expected to move from partnership to actual launch.
- Teriparatide launch: All European approvals are in place, with the launch expected within this financial year, specifically in Q4.
- Growth outlook: Management expects more accelerated growth in other regulated markets early next year, with the overall guidance easily met through outperformance in the UK, Australia, and the US.
OneSource: The CDMO Growth Engine
- Capacity sold out: The injectables facility is fully sold out and backordered, as some customers significantly under-forecasted volumes; the company is now working to debottleneck operations to meet demand.
- GLP demand surge: Estimating demand is difficult, but Liraglutide is seeing unexpectedly higher volume because the dose requirement is double; customers have already started booking capacity at risk for Semaglutide, with launches possible as early as August of next year.
- Capacity expansion funded by customers: Incremental capacity is now being funded through take-or-pay agreements, with management telling customers they must participate in capex to reserve capacity, a dynamic that reflects the extreme demand environment.
- GLP sell-out accelerated: The 4 crore unit capacity is likely to be sold out 6 to 8 months ahead of the original schedule.
- Commercialization timeline: Liraglutide commercialization begins in Q4; 5 to 7 commercial supply agreements for GLPs are expected in FY '26, with Semaglutide commercialization possible in some countries starting January to March '26, aligned with patent expiries in Canada and other markets.
- Non-GLP business filling fast: The 7,000 to 8,000 liter mammalian and microbial capacity is being filled, with microbial capacity being increased to 4,000 liters and expected to be fully sold out within the next 12 months.
- First novel biologic win: The company won its first novel biologic CDMO program for a large company, covering a full late-stage development and commercialization program.
Arun Kumar: "you should strongly believe that all engines are on fire and yes this is a good space to be. And I think we are all very excited about every small bit of our business in OneSource."
The Biosecurity Act Opportunity
- Demand inflection: Interest from customers and RFPs increased beyond expectations since the Biosecurity Act came into play, with the company actively closing out opportunities across drug substance and injectables.
- Win ratio: Management disclosed a 40% win ratio, describing it as "quite a good number for a new CDMO player."
- Pricing strategy: The company is not leading contract wins by price but by service, and pricing is not necessarily low, suggesting the demand environment supports healthy economics.
- First major European contract: The company is securing its first major European contract, with more granularity to be provided soon, marking a geographic expansion potentially linked to the China-plus-one trend.
Softgel CDMO: A New Vertical
- Strategic shift: After 20-plus years in soft gelatins, Strides never offered the capacity as a CDMO opportunity; global capacity disruption has now led to a significant intake of capacity requests and RFPs.
- First customer onboarded: One of the world's largest consumers of soft gelatins has been onboarded as the first CDMO customer, with commercial shipments already underway.
- Revenue split and governance: The business is now roughly half Strides and half outside customers; all new contracts are exclusively with third parties, and Strides will only act as a logistics partner for its own legacy products to avoid related-party issues, with economics staying within OneSource.
- Capacity expansion: Soft gelatin capacity expansion has been completed, with plans to increase by another 100 crore units for next year, and the additional capacity is already sold out.
Financial Health & Capital Allocation
- Debt reduction: Debt has been brought down from INR 3,000 crores to INR 1,500 crores over the last three years purely through operational efficiencies, a testament to the company's focus on cash generation.
- Net cash target: The company expects to be net cash by FY '27.
- OneSource capital raise: The successful raise brought in marquee investors and released close to approximately $700 million in value to Strides shareholders.
- Capex plan: Approximately $100 million is required, funded through a combination of customer advances, a $50 million investment, and free cash from the business post-merger.
- Interest costs: Lower at INR 54 crores this quarter, aided by interest income on tax refunds, but expected to rise in H2 and going forward.
- Gross margin: Declined 75 bps sequentially due to a slightly elevated access market business and lower European sales; the steady-state target remains 59% to 60%.
Arun Kumar: "We would have brought down debt in the last 3 years from a high of INR3,000 crores to INR1,500 crores just through internal operations – I mean, operational efficiencies, which is also a testament to our teamwork here, our great focus on efficiencies and compliance."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Overall EBITDA guidance | INR 950 crores to INR 1,000 crores, including OneSource; trending toward higher end | FY '25 |
| Retained business EBITDA | INR 750 crores to INR 800 crores; business will continue to grow from that size | FY '25 |
| OneSource EBITDA | $59 million to $60 million, trending toward higher end; exit quarter EBITDA of $20 million | FY '25 |
| OneSource exit quarter EBITDA run rate | Very close to 40% | As early as FY '25 |
| Net debt-to-EBITDA | Tracking ahead of guidance of less than 2x | FY '25 |
| Effective tax rate | Remain in 17% to 20% range | FY '25 |
| NCLT process outcome | Positive news expected; stock listing within 60 days of outcome | Before end of calendar year 2024 |
| Teriparatide European launch | All approvals in place | Q4 FY '25 |
| Liraglutide commercialization | Starting from Q4 | Q4 FY '25 |
| GLP capacity sell-out | 4 crore units sold out, 6 to 8 months ahead of schedule | Ahead of original schedule |
| Semaglutide commercialization | Possible in some countries aligned with patent expiry | January to March '26 |
| Net cash target | Company expects to be net cash | By FY '27 |
| $400 million revenue strategy | Reaffirmed | FY '27-'28 |
| OneSource revenue target | $350 million to $400 million | Over next 3 to 4 years |
Key Metrics
| Metric | Q2 FY25 |
|---|---|
| Revenue (US) | $75 million for the year |
| H1 revenue growth | 17% |
| EBITDA | ₹236 cr, highest ever reported |
| H1 EBITDA | ₹452 cr, 45–47% of guided range |
| Reported PAT | ₹93 cr |
| Adjusted PAT (ex-OneSource depreciation and interest) | ₹100 cr, highest ever reported |
| Gross margin | 59–60% target range; 75 bps sequential decline due to elevated access market business and lower European sales |
| EBITDA guidance (FY25, including OneSource) | ₹950 cr to ₹1,000 cr |
| Retained business EBITDA guidance (FY25) | ₹750 cr to ₹800 cr |
| US commercialized products | 71, up from new approvals and dormant product launches |
| US revenue milestone (FY27–28) | $400 million strategy reaffirmed |
| Other regulated markets growth | 3–4% short of target growth rate |
| OneSource revenue guidance (FY25) | $160 million to $180 million with 34% EBITDA margin |
| OneSource EBITDA guidance (FY25) | $59 million to $60 million, exit quarter EBITDA of $20 million |
| OneSource annualized exit run rate | $80 million |
| OneSource revenue target (3–4 years) | $350 million to $400 million |
| OneSource exit quarter EBITDA margin | ~40% |
| CDMO win ratio | ~40% |
| Softgel capacity expansion | Additional 100 crore units planned for next year; current additional capacity fully sold out |
| Cash-to-cash cycle | 126 days |
| Cash flow from operations (H1) | ₹418 cr on H1 EBITDA of ₹453 cr |
| Capex spend (H1) | ₹92 cr |
| Net debt | ₹1,902 cr, reduction of ₹133 cr in H1 |
| Net Debt-to-EBITDA | 2.1x, tracking ahead of <2x guidance for FY25 |
| ROCE | 17.2%, improved from 12.8% in FY24 |
| Net interest costs (quarter) | ₹54 cr, aided by interest income on tax refunds |
| Effective tax rate | 17%, expected to remain in 17–20% range for FY25 |
| GLP commercial supply agreements expected in FY26 | 5 to 7 unique customers |
| Contracted GLPs | 7 out of 8 commercially |
| Revenue growth guidance (FY25) | 15%, trending at 17% toward higher end |